{"id":"NCT00496054","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)","officialTitle":"Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With Rotateq (V260) in Healthy Infants in India","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2007-07-04","resultsPosted":"2010-03-11","lastUpdate":"2017-04-13"},"enrollment":110,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Gastroenteritis","Rotavirus"],"interventions":[{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":["RotaTeq™ Vaccine","V260"]}],"arms":[{"label":"RotaTeq™ Vaccine (V260)","type":"EXPERIMENTAL"}],"summary":"To observe the safety, tolerability and immunogenicity of the administration of 3 doses of rotateq in healthy Indian infants between 6 weeks through exactly 12 weeks of age at entry.","primaryOutcome":{"measure":"The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA","timeFrame":"Baseline and Approximately 6 Months","effectByArm":[{"arm":"RotaTeq™ Vaccine (V260)","deltaMin":82.35,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23442588"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":104},"commonTop":["Diarrhoea","Vomiting","Pyrexia","Nasopharyngitis","Cough"]}}